IASLC WCLC 2016
December 4-7, 2016

Registration Open

IASLC Lung Cancer News
Issue #2

IASLC Foundation

 

 

 Donate Now

 

We are a global network of specialists working together to conquer lung and thoracic cancers worldwide.

LALCA 2016
August 25-27, 2016

Late/Onsite Registration Still Available

More Details

 

IASLC 2016 Chicago Meeting
September 22-24, 2016

Abstract Deadline: August 1, 2016

MORE DETAILS 

Multidisciplinary Live Learning:

Molecular Testing and Personalized Therapy in Lung Cancer

d

More Information

Featured Science and Communiqués

Lymph Node Stage May Have Clinical Significance Among NSCLC Patients with Stage IV M1a Disease

DENVER – Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.

Leptomeningeal Metastases Are More Common in NSCLC Patients Harboring EGFR Mutations and Respond Positively to TKI Therapy

DENVER – Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Patients receiving tyrosine kinase inhibitors (TKIs) targeting EGFR mutations had a longer overall survival (OS) than those who did not receive TKIs, demonstrating the effectiveness of TKIs for LM therapy.

Liquid Biopsies for the Identification of EGFR Mutations and for the Prediction of Lung Cancer Recurrence

DENVER – Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. Collectively, these findings illustrate the potential and reach of liquid biopsies in both identifying patients suitable for targeted treatment as well as predicting cancer recurrence.

Nivolumab Cost-Effectiveness Improves by Selecting Non-Squamous NSCLC PD-L1+ Patients to Receive Treatment

DENVER – Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price.